Advanced Search

 

Study ID Status Title Patient Level Data
VEG105427 Completed A Phase I, Open-Label, Study of the Safety, Tolerability, and Pharmacokinetics of Pazopanib in Combination with Paclitaxel on a Weekly Schedule for Three Consecutive Weeks of a 28-Day Cycle, Paclitaxel and Carboplatin on an Every 21 Days Schedule and Lapatinib and Paclitaxel on a Weekly Schedule for three Consecutive Weeks of a 28- Day Cycle
VEG105430 Active, Not Recruiting An Open-Label, Phase Ib Study to Assess the Long Term Safety Profile of Pazopanib in Cancer Patients
VEG107200 Completed A Phase I, Open-Label, Dose-Escalation, Multi-Center Study or Pazopanib (GW786034) in Adult Patients with Hepatocellular Cancer
VEG107769 Completed An open-label extension study to assess the safety and efficacy of pazopanib in subjects with renal cell carcinoma previously enrolled on protocol VEG105192
VEG108838 Completed A Randomized, Multicenter, Phase III Study Comparing the Combination of Pazopanib and Lapatinib versus Lapatinib Monotherapy in Patients with ErbB2 over-expressing Inflammatory Breast Cancer
VEG108843 Withdrawn A randomized, double-blind, placebo-controlled, multicenter Phase II study to compare the efficacy and tolerability of pazopanib administered in combination with exemestane versus exemestane plus placebo in postmenopausal subjects with advanced or metastatic hormone receptor positive breast cancer
VEG108925 Completed Phase I study of Safety and Pharmacokinetics of pazopanib in combination with Cetuximab and irinotecan in patients with colorectal cancer
VEG109599 Completed A Phase I, Open-label, Study of the Safety, Tolerability and Pharmacokinetics of Pazopanib in Combination with Gemcitabine and Gemcitabine plus Cisplatin for Advanced Solid Tumors
VEG109603 Completed A Phase I, Open-label, Study of the Safety, Pharmacokinetics, and Pharmacodynamics dose escalation of Pazopanib in Combination with Epirubicin or Doxorubicin for Advanced Solid Tumors
VEG109607 Completed A Phase I Study of Pazopanib in Combination with Either Erlotinib or Pemetrexed in Patients with Advanced Solid Tumors
VEG110190 Completed A Phase I/II, Open-Label, Multicenter, Two-Arm, Feasibility Study of Pazopanib, Carboplatin, and Paclitaxel in Women with Newly Diagnosed, Previously Untreated, Gynaecological Tumors
VEG110727 Completed A Randomized Double Blind Phase III Trial of Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy
VEG20002 Completed Phase II study of GW786034 in patients with relapsed or refractory soft tissue sarcoma
VEG20006 Completed A Phase II, Open-Label Study of Pazopanib (GW786034) in Patients with Relapsed or Refractory Multiple Myeloma
VEG20007 Completed A Phase II, Open-Label, Randomized, Multicenter Trial of GW786034 (Pazopanib) in Combination with Lapatinib (GW572016) Compared to Lapatinib Alone as First Line Therapy in Subjects with Advanced or Metastatic Breast Cancer with ErbB2 Fluorescence In Situ Hybridization (FISH) Positive Tumors
VLX103596 Completed Valacyclovir for the Suppression of HSV-2 Viral Shedding in HSV-2 Seropositive Individuals with No History of Symptomatic GH Study Listed on ClinicalStudyDataRequest.com
VLX105832 Completed The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed with Genital Herpes Infection Study Listed on ClinicalStudyDataRequest.com
VRA105345 Completed A multi-centre, randomised, single blind, placebo controlled, parallel group study to examine the effect of single doses of SB-705498, a TRPV1 receptor antagonist, on pain following third molar tooth extraction
VRA107438 Terminated A double-blind, randomised, placebo controlled, single dose, two-period crossover study to investigate the therapeutic potential of the TRPV1 antagonist SB-705498 in treatment of subjects with rectal hypersensitivity including irritable bowel syndrome. Study Listed on ClinicalStudyDataRequest.com
VRX-RET-E22-301 Completed A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study to Determine the Efficacy and Safety of Retigabine (1200 mg/day) Used as Adjunctive Therapy in Refractory Epilepsy Patients with Partial-Onset Seizures Study Listed on ClinicalStudyDataRequest.com
VRX-RET-E22-302 Completed Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study - Determine Efficacy and Safety of Two Doses of Retigabine (900 Mg/Day and 600 Mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients with Partial-Onset Seizures Study Listed on ClinicalStudyDataRequest.com
VRX-RET-E22-303 Completed A multicenter, open-label, long-term, safety, tolerability and efficacy study of retigabine in adult epilepsy patients with partial-onset seizures (Extension of study VRX-RET-E22-301)
VRX-RET-E22-304 Active, not recruiting A Multicenter, Open-Label, Long-Term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-Onset Seizures (Extension of Study VRX-RET-E22-302) Study Listed on ClinicalStudyDataRequest.com
W2650782 Completed A pharmacokinetic study of two oral formulations of orlistat
W2651062 Completed A Study to Assess the Pharmacodynamic Equivalence of Two Orlistat Dosage Forms

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.